- Who We Are
- What We Do
- How To Help
- Contact Us
NEW GRANTS TOTALING $2.1 MILLION ANNOUNCED
In 2017, the Foundation's Medical Advisory Board selected seven of the nation's top junior investigators to receive our three-year, $225,000 Medical Research Award. The Foundation also announced support for eight one-year grants; the Director's Innovation Fund at the Sylvester Comprehensive Cancer Center in Miami, FL; one ASBMT New Investigator Award; three music therapy programs; and assorted symposia and medical conferences.
Click here for a full list of this year's grant recipients and read our press release here. Learn more about our Medical Research Award recipients & their proposed projects here.
“We have fostered an entire generation of cancer researchers and fueled their scientific breakthroughs,” said Medical Advisory Board Chairman, Dr. Stephen Nimer. “The future of cancer research has never been brighter and we are helping lead the way.” Read all the latest scientific news and breakthroughs from the labs of our Foundation-funded research scientists in these monthly medical updates.
In 2012, two teams of former grantees received Collaborative Grant Awards totaling $800,000 made possible by a generous gift from the Marc Rich Foundation. Each team received $400,000 over two years. Medical Advisory Board chair Stephen D. Nimer, M.D. remarked, “What is particularly exciting about these new collaborative grants is that they not only prove the value of the initial investment, they bring scientists and institutions together to significantly accelerate and broaden the impact of their work.”
Ari Melnick, M.D. of Weill Cornell Medical College, Ross Levine, M.D. of Memorial Sloan Kettering Cancer Center and Chuan He, Ph.D. from The University of Chicago were awarded a grant for their project entitled “Decoding the hydroxymethylome of IDH and TET mutant acute leukemias.” Anthony Letai, M.D. of Dana-Farber Cancer Institute worked with Memorial Sloan Kettering’s Scott Armstrong, M.D. on a project where they propose “a completely novel approach to identifying the chemotherapy resistant subsets in [acute myelogenous] leukemia patient samples, identifying the mechanisms making them resistant to chemotherapy, and targeting those mechanisms.”
The Foundation hopes to offer another such collaborative grant in the future.